Tumor Biology

, Volume 34, Issue 6, pp 3309–3316 | Cite as

The VDR gene FokI polymorphism and ovarian cancer risk

  • Hui Xu
  • Su Li
  • Jian-Qing Qiu
  • Xiao-Lin Gao
  • Ping Zhang
  • Yong-Xia Yang
Research Article

Abstract

The polymorphism of vitamin D receptor (VDR) gene is demonstrated to affect the activity of its encoding protein and the subsequent downstream effects mediated by vitamin D. Mutations in VDR gene FokI have been suggested in the development of various cancers. Whether the polymorphism of the VDR gene FokI confers risk to ovarian cancer still remains controversial across the published studies in different ethnicity. The aim of this meta-analysis was to determine the role of VDR gene FokI variant in the susceptibility to ovarian cancer. Six publications with 14 individual case–control studies involving a total of 10,964 subjects were finally included into our study after a comprehensive literature search of the PubMed, Embase, Web of Science, and Wanfang databases. The strength of the association between the VDR gene FokI polymorphism and ovarian cancer risk was estimated under the allelic (T vs. C), homozygous (TT vs. CC), additive (CT vs. CC), recessive (TT vs. CC + CT), and dominant (CT + TT vs. CC) gene models. The overall odds ratios (ORs) for the contrast models of T vs. C, TT vs. CC, CT vs. CC, and CT + TT vs. CC indicated that the VDR gene FokI variant was related to an increased risk of ovarian cancer (ORT vs. C = 1.09, 95 % confidence interval (CI) 1.03–1.15, P OR = 0.004; ORTT vs. CC = 1.17, 95 % CI 1.04–1.32, P OR = 0.011; ORCT vs. CC = 1.10, 95 % CI 1.01–1.20, P OR = 0.027; ORCT + TT vs. CC = 1.12, 95 % CI 1.03–1.21, P OR = 0.007). The stratified analysis among the Caucasians also identified a significant association between the VDR gene FokI polymorphism and the susceptibility to ovarian cancer. The present meta-analysis with large available published data has revealed that the VDR gene FokI polymorphism confers susceptibility to ovarian cancer, particularly among the Caucasian population.

Keywords

Ovarian cancer Vitamin D receptor FokPolymorphism Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Westhoff C. Ovarian cancer. Annu Rev Public Health. 1996;17:85–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin N Am. 2012;26:1–12.CrossRefGoogle Scholar
  4. 4.
    Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79.PubMedCrossRefGoogle Scholar
  5. 5.
    Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor—a review. Placenta. 2008;29 Suppl B:169–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Shen N, Weiderpass E, Antilla A, Goldberg MS, Vasama-Neuvonen KM, Boffetta P, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24:175–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Shields T, Gridley G, Moradi T, Adami J, Plato N, Dosemeci M. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42:200–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med. 2012;271:366–78.PubMedCrossRefGoogle Scholar
  9. 9.
    Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne). 2012;3:58.Google Scholar
  10. 10.
    Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16:1–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992;33:1660–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18:1672–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol. 2010;16:3016–24.PubMedCrossRefGoogle Scholar
  15. 15.
    McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297–305.PubMedCrossRefGoogle Scholar
  16. 16.
    Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4:e103.PubMedCrossRefGoogle Scholar
  17. 17.
    Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMedGoogle Scholar
  18. 18.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  19. 19.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  21. 21.
    Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260:209–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69:1885–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol. 2012;129:173–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet Test Mol Biomark. 2013;17:183–7.CrossRefGoogle Scholar
  27. 27.
    Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997;11:1165–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–59.PubMedCrossRefGoogle Scholar
  29. 29.
    Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86:40–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Kocabas A, Karaguzel G, Imir N, Yavuzer U, Akcurin S. Effects of vitamin D receptor gene polymorphisms on susceptibility to disease and bone mineral density in Turkish patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:1289–97.PubMedGoogle Scholar
  31. 31.
    Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90:187–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Ralston SH. The genetics of osteoporosis. QJM. 1997;90:247–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMedGoogle Scholar
  35. 35.
    Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.PubMedCrossRefGoogle Scholar
  36. 36.
    Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92:49–59.PubMedCrossRefGoogle Scholar
  38. 38.
    Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci. 1990;592:363–75. discussion 90–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717–21.PubMedGoogle Scholar
  40. 40.
    Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Romanowicz-Makowska H, Smolarz B, Samulak D, Michalska M, Lewy J, Burzynski M, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33:406–10.PubMedGoogle Scholar
  42. 42.
    Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet. 2005;77:807–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000;14:401–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203–16.PubMedCrossRefGoogle Scholar
  46. 46.
    Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res. 1998;13:1691–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Hui Xu
    • 1
  • Su Li
    • 1
  • Jian-Qing Qiu
    • 1
  • Xiao-Lin Gao
    • 1
  • Ping Zhang
    • 1
  • Yong-Xia Yang
    • 1
  1. 1.Department of Obstetrics and GynecologyThe Second Hospital of Shandong UniversityJinanChina

Personalised recommendations